French Electronic Equipment and Components Stock News

Investors were underwhelmed by the solid earnings posted by SergeFerrari Group SA ( EPA:SEFER ) recently. We have done...

The market for Capgemini SE's ( EPA:CAP ) shares didn't move much after it posted weak earnings recently. We think that...

One of the biggest stories of last week was how STIF Société anonyme ( EPA:ALSTI ) shares plunged 26% in the week since...

As the European markets navigate through uncertainties spurred by geopolitical tensions and energy price fluctuations, investor sentiment remains cautious yet discerning. In such a climate, growth companies with high insider ownership often stand out as potentially resilient investments due to the alignment of interests between insiders and shareholders, which can be particularly advantageous during periods of economic volatility.

The European markets have been navigating a landscape marked by geopolitical tensions and fluctuating energy prices, with the pan-European STOXX Europe 600 Index showing modest gains. Amidst this backdrop, investors are increasingly looking at diverse investment avenues to capitalize on potential opportunities. Penny stocks, often representing smaller or newer companies, remain an intriguing area for those seeking growth at lower price points. Although the term might seem outdated, these...

Today is shaping up negative for 2CRSI S.A. ( EPA:AL2SI ) shareholders, with the analysts delivering a substantial...

As you might know, Cegedim SA ( EPA:ALCGM ) last week released its latest full-year, and things did not turn out so...

Bolloré (ENXTPA:BOL) has drawn fresh attention after its board proposed an exceptional €1.5 per share dividend, about €4.2b, alongside 2025 results and a regular €0.08 per share dividend plan. See our latest analysis for Bolloré. The exceptional dividend proposal and 2025 earnings release have arrived after a mixed period, with a 3.96% three month share price return, a 1.17% year to date share price gain, but a 1 year total shareholder return decline of 11.46%, suggesting short term momentum...

Recent share performance and current context Pernod Ricard (ENXTPA:RI) has seen its share price move unevenly, with a roughly flat 7 day return, a double digit decline over the past month, and a smaller negative move across the past 3 months. See our latest analysis for Pernod Ricard. The recent 7.9% 1 day share price return to €64.7 comes after a 17.3% 30 day share price decline and sits against a 27.4% 1 year total shareholder return loss, suggesting momentum has been fading over a longer...

Sanofi received FDA Breakthrough Therapy designation for oral venglustat targeting neurological symptoms in type 3 Gaucher disease. Sanofi reported positive phase 3 results for amlitelimab in atopic dermatitis. European regulators issued a positive opinion for Sarclisa subcutaneous with an on body injector for multiple myeloma, potentially introducing dual administration modes in the EU. Sanofi, traded as ENXTPA:SAN, is currently priced at €81.99 and has seen a 5.4% gain over the past week,...

Kering (ENXTPA:KER) has drawn investor attention after recent share price swings, with the stock down over the past month and past 3 months, despite a positive 1 year total return profile. See our latest analysis for Kering. The current share price of €248.3 sits against a 7 day share price return of 6.04%, while the 30 day and year to date share price returns of 13.15% and 18.48% point to fading short term momentum despite a 1 year total shareholder return of 27.89% and weaker 3 and 5 year...

If you are wondering whether ABIVAX Société Anonyme is priced attractively right now, the starting point is to compare what you pay today with what the business could be worth under different valuation lenses. The stock last closed at €89.20, after a 7 day return of an 18.5% decline and a 30 day return of a 13.1% decline, set against a very large 1 year gain and an 11.8x return over 3 years. Recent attention on ABIVAX Société Anonyme has been shaped by ongoing coverage of its position in the...

Ipsen (ENXTPA:IPN) has come into focus after presenting fresh preclinical data at the AACR congress for two first in class oncology candidates, IPN01203 and IPN60300, targeting difficult solid tumor indications. See our latest analysis for Ipsen. The latest oncology data and recent conference activity come at a time when Ipsen’s share price has reached €157.7, with recent momentum reflected in a 90 day share price return of 32.97% and a 1 year total shareholder return of 48.68%. This...

Publicis Groupe has appointed Deepraj Hegde as senior vice president, strategic solutions. Hegde will focus on data driven growth, digital transformation and strengthening client partnerships. His remit includes advancing analytics, consumer insight and digital strategy to improve measurable outcomes. Publicis Groupe, listed as ENXTPA:PUB, is trading around €68.56, with the share price showing a 21.8% decline year to date and a 20.8% decline over the past year. These moves come after...

What recent moves in Valeo’s share price tell you Valeo (ENXTPA:FR) has seen mixed share price performance recently, with gains over the past week but weaker moves over the past month and past 3 months, which is prompting closer attention from investors. See our latest analysis for Valeo. At a share price of €10.225, Valeo’s recent 7 day share price return of 4.34% sits against weaker 30 day and year to date share price returns. The 1 year total shareholder return of 20.41% contrasts with...

If you are wondering whether Arkema at €58.20 is a bargain or a value trap, you will want to look closely at what different valuation checks are saying about the stock. The share price has had a mixed run, with a 15.2% gain over the last 7 days, an 11.2% return year to date, but a 14.2% decline over the past year. Recent coverage has focused on how Arkema is positioned within the broader Chemicals sector and how investors are reassessing companies in the space in light of evolving demand...

Parrot (ENXTPA:PARRO) has opened FY 2025 with first half revenue of €33.6 million and a basic EPS loss of €0.47. This helps frame how you might think about the rest of the year after recent swings between profit and loss. Over the past three reported halves, revenue has moved from €30.6 million in H1 2024 to €47.5 million in H2 2024 and now €33.6 million in H1 2025. Over the same period, basic EPS has shifted from a €0.33 loss in H1 2024 to a modest €0.03 profit in H2 2024 before returning to...

Thales has partnered with the Dominican Republic to launch the country's first electronic passport, integrating advanced cybersecurity for citizen data. The project establishes a secure e-passport system and ongoing cyber threat monitoring for the Dominican Republic's border and identity infrastructure. For investors tracking ENXTPA:HO, this agreement adds additional real world evidence of Thales' role in digital identity and security, alongside its existing defense and aerospace...

Investors in Innate Pharma S.A. ( EPA:IPH ) had a good week, as its shares rose 2.4% to close at €1.10 following the...

It's been a pretty great week for Netgem SA ( EPA:ALNTG ) shareholders, with its shares surging 11% to €0.76 in the...

Investors in Arverne Group S.A. ( EPA:ARVEN ) had a good week, as its shares rose 2.9% to close at €5.25 following the...

LVMH Moët Hennessy - Louis Vuitton Société Européenne (ENXTPA:MC) is contending with strong luxury demand in India alongside a shortage of prime retail space. High quality luxury malls are in short supply, and new projects are planned but not yet available for brands to occupy. The situation is creating both near term constraints and longer term opportunities for LVMH and other global luxury groups targeting India. For LVMH, which spans fashion, leather goods, spirits, beauty and watches,...

If you are wondering whether Elis at €24.12 is still offering value or if most of the opportunity has already been priced in, this article breaks that question down in plain terms. The share price is up 1.3% over the last week, while the 30 day return sits at an 11.2% decline. This is set against longer term returns of 1.3% year to date, 17.7% over 1 year, 45.5% over 3 years and 83.9% over 5 years. Recent coverage around Elis has focused on its role within commercial services and how...

Wondering if Vinci at €126.10 offers fair value or a margin of safety right now? This article breaks down what the current price could imply for you as a shareholder. The stock has returned 1.7% over the past week, while the 30 day return stands at an 11.1% decline. Year to date, 1 year, 3 year and 5 year returns are 4.1%, 10.6%, 34.2% and 68.3% respectively. Recent coverage has focused on Vinci's position as a major European infrastructure and concessions group, including ongoing interest...